Authors' Reply to Godman and Gustafsson: "A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing''

被引：0

作者：

Persson, Ulf ^{[1
,2
]}

Svensson, Johanna ^{[2
]}

Pettersson, Billie ^{[3
]}

机构：

[1] Lund Univ, Sch Econ & Management, Lund Inst Econ Res, Lund, Sweden

[2] Swedish Inst Hlth Econ, S-22002 Lund, Sweden

[3] MSD, Sollentuna, Sweden

来源：

APPLIED HEALTH ECONOMICS AND HEALTH POLICY | 2013年 / 11卷 / 01期

关键词：

D O I：

10.1007/s40258-013-0009-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：83 / 84

页数：2

共 11 条

[1] Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”
Ulf Persson
Johanna Svensson
Billie Pettersson
Applied Health Economics and Health Policy, 2013, 11 (1) : 83 - 84
[2] A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Brian Godman
Lars L. Gustafsson
Applied Health Economics and Health Policy, 2013, 11 (1) : 79 - 82
[3] A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Persson, Ulf
Svensson, Johanna
Pettersson, Billie
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2012, 10 (04) : 217 - 225
[4] A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Ulf Persson
Johanna Svensson
Billie Pettersson
Applied Health Economics and Health Policy, 2012, 10 (4) : 217 - 225
[5] A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
Godman, Brian
Gustafsson, Lars L.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2013, 11 (01) : 79 - 82
[6] Using Pharmacoeconomic Modelling to Determine Value-Based Pricing for New Pharmaceuticals in Malaysia
Dranitsaris, George
Truter, Ilse
Lubbe, Martie S.
Sriramanakoppappa, Nitin N.
Mendonca, Vivian M.
Mahagaonkar, Sangameshwar B.
MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2011, 18 (04): : 32 - 43
[7] Convergence of decision rules for value-based pricing of new innovative drugs
Gandjour, Afschin
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 209 - 213
[8] Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’
Bonny Parkinson
Adam G. Elshaug
PharmacoEconomics, 2016, 34 : 421 - 422
[9] Authors' Reply to Palozzo and Messori: "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review"
Parkinson, Bonny
Elshaug, Adam G.
PHARMACOECONOMICS, 2016, 34 (04) : 421 - 422
[10] Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"
Levaggi, Rosella
Pertile, Paolo
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (03) : 455 - 456

← 1 2 →